Artificial intelligence has become a fixture of nearly every pharma company’s investor presentation, but the actual impact on drug discovery varies enormously depending on which stage of the pipeline the technology is applied to, a distinction that gets lost in most general coverage of the topic.

AI has shown the clearest, most reproducible impact in target identification and early hit discovery, where machine learning models can screen vastly larger chemical and biological search spaces than traditional methods, meaningfully compressing the time from initial target identification to lead compound selection.

The picture becomes less clear further downstream. AI-assisted design can propose promising candidate molecules faster, but it has not meaningfully shortened the actual clinical trial timeline, since Phase 1 through Phase 3 development still requires the same years of patient enrollment, dosing, and follow-up that traditional drug development has always required.

Some of the more credible claims involve using AI to improve patient selection and trial design itself, identifying biomarker subgroups more likely to respond or predicting enrollment challenges before a trial begins, applications that improve trial efficiency and success rates without claiming to shorten biology’s own timelines.

Investors and industry observers should be particularly skeptical of claims that AI has fundamentally solved drug discovery’s core productivity problem, since the industry’s historical approval success rate from Phase 1 to approval remains in the range of 10 percent, and no AI-discovery-driven asset has yet compiled a large enough track record through Phase 3 to demonstrate a structurally different success rate.

Trend Watch coverage that separates genuine AI-driven efficiency gains from promotional language, tracking which AI-discovered assets are actually advancing through clinical trials rather than just entering them, such as the ongoing analysis from The Pharma Vanguard, offers a more grounded view of where the technology is delivering real value today.